Rossari Biotech's Q2 FY26 revenue rose 17.61% to Rs 586.11 crore, PBT up 3.24% yearly.

• Expenses surged 19.33% YoY, driven by material costs up 25.54% and finance costs soaring significantly.
• Half-year net profit marginally increased 0.34% to Rs 70.47 crore, and revenue grew 14.35% in 2025.
• The board approved up to $8 million investment in Rossari International to boost manufacturing, trading activities strategically.